These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10779307)

  • 1. The renin angiotensin system and hymenoptera venom anaphylaxis.
    Hermann K; Ring J
    Clin Exp Allergy; 1993 Sep; 23(9):762-9. PubMed ID: 10779307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between the renin angiotensin system and anaphylaxis.
    Hermann K; Ring J
    Adv Exp Med Biol; 1995; 377():299-309. PubMed ID: 7484432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The renin-angiotensin system in patients with repeated anaphylactic reactions during hymenoptera venom hyposensitization and sting challenge.
    Hermann K; Ring J
    Int Arch Allergy Immunol; 1997 Mar; 112(3):251-6. PubMed ID: 9066511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histamine, tryptase, norepinephrine, angiotensinogen, angiotensin-converting enzyme, angiotensin I and II in plasma of patients with hymenoptera venom anaphylaxis.
    Hermann K; von Tschirschnitz M; Ebner von Eschenbach C; Ring J
    Int Arch Allergy Immunol; 1994 Aug; 104(4):379-84. PubMed ID: 7913643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hymenoptera venom anaphylaxis: may decreased levels of angiotensin peptides play a role?
    Hermann K; Ring J
    Clin Exp Allergy; 1990 Sep; 20(5):569-70. PubMed ID: 2253089
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
    Spoerl D; Bircher AJ; Scherer K
    J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The circulating renin-angiotensin system and the response to hypotension.
    Waller DG
    Clin Exp Allergy; 1993 Sep; 23(9):718-21. PubMed ID: 10779301
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of venom immunotherapy on serum level of CCL5/RANTES in patients with Hymenoptera venom allergy.
    Gawlik R; Glück J; Jawor B; Rogala B
    Immunopharmacol Immunotoxicol; 2015; 37(4):375-9. PubMed ID: 26181651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The angiotensinogen AGT p.M235T gene polymorphism may be responsible for the development of severe anaphylactic reactions to insect venom allergens.
    Niedoszytko M; Ratajska M; Chełmińska M; Makowiecki M; Malek E; Siemińska A; Limon J; Jassem E
    Int Arch Allergy Immunol; 2010; 153(2):166-72. PubMed ID: 20413984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
    Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
    Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrarush immunotherapy in patients with Hymenoptera venom allergy.
    Ruëff F; Przybilla B
    J Allergy Clin Immunol; 2001 May; 107(5):928-9. PubMed ID: 11344369
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma concentrations of arginine vasopressin, oxytocin and angiotensin in patients with hymenoptera venom anaphylaxis.
    Hermann K; von Eschenbach CE; von Tschirschnitz M; Ring J
    Regul Pept; 1993 Nov; 49(1):1-7. PubMed ID: 8278629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
    Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
    J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hymenoptera venom allergy].
    Sieber W; Brunner M
    Dtsch Med Wochenschr; 2019 Aug; 144(15):1051-1054. PubMed ID: 31350747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.
    Sturm G; Kränke B; Rudolph C; Aberer W
    J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Follow-Up of Children after Venom Immunotherapy: Low Adherence to Anaphylaxis Guidelines.
    Fiedler C; Miehe U; Treudler R; Kiess W; Prenzel F
    Int Arch Allergy Immunol; 2017; 172(3):167-172. PubMed ID: 28380475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Desensitization of allergy to hymenoptera venoms].
    Przybilla B; Ruëff F
    Wien Med Wochenschr; 1999; 149(14-15):421-8. PubMed ID: 10584286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Hymenoptera venom rush immunotherapy.
    Laurent J; Smiejan JM; Bloch-Morot E; Herman D
    Allergy; 1997 Jan; 52(1):94-6. PubMed ID: 9062635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
    von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
    Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-evaluation of the plasma renin-angiotensin system in anephric patients.
    Mizuno K; Higashimori K; Stone WJ; Shimamoto K; Fukuchi S; Inagami T
    Clin Exp Hypertens A; 1990; 12(7):1135-57. PubMed ID: 2257684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.